Proteins with diagnostic and therapeutic uses
AssigneeThe University Court of the University of Edinburgh
InventorsPaul Barlow, Andrew Herbert, Elisavet Makou
Life of this patent
Estimating the term…
Abstract
The present invention provides a recombinant protein capable of binding to complement factor H (CFH), and thereby inducing increased binding of C3d and C3b by bound CFH compared to unbound CFH. Methods and medical devices for using utilising the same are also described.
Claims48
A recombinant protein capable of binding to complement factor H (CFH), and thereby inducing increased binding of C3d and C3b by bound CFH compared to unbound CFH.
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
A composite comprising a recombinant protein bound to complement factor H (CFH), the composite inducing increased binding of C3d and C3b by bound CFH compared to unbound CFH, wherein CFH is held in a conformation, or conformations, that is/are more active than the conformation or conformations adopted by CFH alone.
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
A medical device, wherein a surface of the medical device is at least partially coated with a recombinant protein capable of binding to complement factor H (CFH), and thereby inducing increased binding of C3d and C3b by bound CFH compared to unbound CFH.
A method of treating a medical device, the method comprising:
- providing a medical device;
- providing a protein capable of binding to complement factor H (CFH), and thereby inducing increased binding of C3d and C3b by bound CFH compared to unbound CFH;
- and
- binding said protein to at least a portion of the surface of the medical device.
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
A pharmaceutical preparation comprising a recombinant protein capable of binding to complement factor H (CFH), and thereby inducing increased binding of C3d and C3b by bound CFH compared to unbound CFH, or a nucleic acid encoding the same.
(canceled)
(canceled)
A method of treatment or prevention of a disease in a subject by administration to a subject of an effective amount of a pharmaceutical composition comprising a recombinant protein capable of binding to complement factor H (CFH), and thereby inducing increased binding of C3d and C3b by bound CFH compared to unbound CFH, or a nucleic acid encoding said recombinant protein.
(canceled)
(canceled)
Dependencies are inferred from the claim text.